Skip to main content

Remote Job Finders (RJF)

Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks

Eli Lilly first linked up with Gate Bioscience in July 2025 to leverage the biotech’s “Molecular Gate” engine to treat diseases with high unmet need. Monday’s expansion will add one undisclosed target to the existing agreement, with an option for a second.

CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

CSL will co-develop and co-promote Alentis Therapeutics’ anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune disease characterized by small blood vessel inflammation.

Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand

A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.

BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.

Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk.

Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.
Scroll to top